Clinical Trials Browser

Completed × olaparib × 90 days × Clear all

NCT04375267 2026-04-14

LuPARP

Phase 1 Completed

EndocrineNETOther solid neoplasmThoracic

Mesothelioma, Thymoma, Neuroendocrine Tumors

NCT03462342 2026-04-13

CAPRI

Phase 2 Completed

High Grade Serous Carcinoma

NCT05340413 2026-03-16

RADIOLA

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04191135 2026-03-03

KEYLYNK-009

Phase 2 Completed

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02787642 2026-02-25

RADIOSARP

Phase 1 Completed

41 enrolled 15 charts

Sarcoma

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 3 Completed

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT03976362 2026-02-25

KEYLYNK-008

Phase 3 Completed

851 enrolled 25 charts

Carcinoma

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

302 enrolled 26 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Breast Neoplasms

NCT03008278 2026-02-03

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Phase 1/2 Completed

51 enrolled 20 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms